SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients

• Type: Article in International Scientific Journal
• Date: 2014

Authors

Lima, A (Author) Other; Bernardes, M (Author) Other; Sousa, H (Author) Other; Azevedo, R (Author) Other; Costa, L (Author) Other; Ventura, F (Author) Other; Seabra, V (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Pharmacogenomics

Vol. 15

Pages: 807-820

ISSN: 1462-2416

Publisher: ASHLEY PUBLICATIONS LTD

Indexing

ISI Web of Knowledge - 28 Citations

Scopus - 29 Citations

Other information

Authenticus ID: P-009-HQJ

DOI: 10.2217/pgs.13.244

Abstract (EN): Aim: The aim of our study was to characterize the association of clinicopathological variables and the SLC19A1/RFC-1 G80A polymorphism in methotrexate (MTX)-related toxicity in Portuguese patients with rheumatoid arthritis. Patients & methods: The study included 233 consecutively recruited patients with rheumatoid arthritis under MTX treatment. The SLC19A1 G80A polymorphism was evaluated by PCR-RFLP. Results: Statistical ana-lysis revealed that SLC19A1 80G carriers had increased risk of gastrointestinal toxicity (odds ratio [OR]: 2.61, p = 0.019) and that regular folic acid supplementation was associated with both overall and gastrointestinal toxicity protection (OR: 0.15, p < 0.001 and OR: 0.19, p < 0.001, respectively). Multivariate ana-lysis confirmed the association of SLC19A1 80G and regular folic acid supplementation to gastrointestinal toxicity (OR: 5.53 and 0.13, respectively). Moreover, a multivariate Cox regression model demonstrated a higher risk of earlier gastrointestinal toxicity in SLC19A1 80G carriers (hazard ratio: 3.63, p = 0.002). Conclusion: SLC19A1 G80A genotyping may be a useful tool for clinicians to identify patients at higher risk for developing gastrointestinal toxicity related to MTX treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14